Acasti announces first fiscal quarter 2025 financial results, provides business update

Princeton, n.j., aug. 09, 2024 (globe newswire) -- acasti pharma inc. (nasdaq: acst) (acasti or the company), a late-stage, biopharma company advancing gtx-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah), today announced financial results and business highlights for the quarter ended june 30, 2024.
ACST Ratings Summary
ACST Quant Ranking